Daniel P. Bezerra has a B.Pharm. and Ph.D in pharmacology, and specializes in the pre-clinical development of new antineoplastic drugs. Currently, he is mainly involved in the study of ruthenium complexes; natural products; oxidative stress; PI3K/AKT/mTOR, MAPK, NFkB and p53 signaling; hepatocellular carcinoma; colon carcinoma; acute myeloid leukemia; and cancer/leukemia stem cells.
Daniel P. Bezerra has a B.Pharm. and Ph.D in pharmacology, and specializes in the pre-clinical development of new antineoplastic drugs. Currently, he is mainly involved in the study of ruthenium complexes; natural products; oxidative stress; PI3K/AKT/mTOR, MAPK, NFkB and p53 signaling; hepatocellular carcinoma; colon carcinoma; acute myeloid leukemia; and cancer/leukemia stem cells.